High Market Potential
Bexion is currently pursuing cancer treatments where there is a significant unmet need and high market potential*.
| Bexion Area of Focus | Unmet Need | Annual Global Market Potential |
|---|---|---|
| DIPG – Diffuse Intrinsic Pontine Glioma | Currently, there are no approved drugs for DIPG
DIPG carries a dismal prognosis, with a 2-year survival rate of <10%, making DIPG one of the most fatal pediatric malignancies. |
$15 Million-Qualify for a Rare Pediatric Voucher |
| Glioblastoma Multiforme (GBM) | GBM average survival is 16-20 months, with only 25% of glioblastoma patients surviving 2 years. | $1 Billion |
| Colorectal | Stage 4 colorectal cancer 5-year survival rate is between 11 and 14%. | $10 Billion |
*BXQ-350 appears to be “tumor-agnostic” suggesting treatments for other types of cancer.